DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity
Marine Yeghiazaryan1, Izabela Rutkowska-Wlodarczyk2, Anna Konopka1
1Department of Neurophysiology, The Nencki Institute of Experimental Biology, Warsaw, Poland.
Plos One
|June 12, 2014
Summary
DP-b99, a chelator of zinc and calcium, reduces seizure severity and protects against excitotoxicity. It may offer therapeutic potential for conditions involving aberrant neuronal plasticity, like epileptogenesis.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Matrix metalloproteinases (MMPs) are zinc-dependent enzymes involved in synaptic plasticity.
- Dysregulated MMP activity contributes to neurological disorders such as stroke, neurodegeneration, and epileptogenesis.
- DP-b99 is a novel membrane-activated chelator of zinc and calcium ions with therapeutic potential.
Purpose of the Study:
- To investigate the therapeutic potential of DP-b99 in neurological conditions.
- To determine DP-b99's effects on seizures and excitotoxicity.
- To explore DP-b99's impact on MMP-9-mediated neuronal plasticity.
Main Methods:
- DP-b99 administration in a mouse model of pentylenetetrazole (PTZ)-induced seizures.
- Assessment of DP-b99's neuroprotective effects on kainate excitotoxicity in hippocampal organotypic slices.
- Evaluation of DP-b99's effect on morphological reorganization of dendritic spines induced by MMP-9.
Main Results:
- DP-b99 significantly delayed the onset and reduced the severity of PTZ-induced seizures in mice.
- DP-b99 demonstrated neuroprotective effects against kainate excitotoxicity in hippocampal slices.
- DP-b99 blocked the morphological reorganization of dendritic spines induced by MMP-9.
Conclusions:
- DP-b99 exhibits anticonvulsant and neuroprotective properties.
- DP-b99 may exert its effects by inhibiting MMP-9 activity and associated aberrant neuronal plasticity.
- DP-b99 warrants further investigation as a therapeutic agent for epileptogenesis and other MMP-driven neurological disorders.
